COVID-19
Conditions
Keywords
COVID-19, Vaccine, Ad5, Immunobridging, Lot-to-lot consistency
Brief summary
The study is a single-center, randomized and double-blinded trial to evaluate the immunobridging between different manufacture scales, lot-to-lot consistency of the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)(Ad5-nCOV) in population 6-59 years of age. The immunobridging between different manufacture scales will be evaluated first, the immunobridging between different age groups will be evaluated second, the lot-to-lot consistency will be evaluated at last.
Interventions
BIOLOGICALRecombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
Containing 0.5E10vp
BIOLOGICALRecombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
Containing 0.3E10vp
Sponsors
Jiangsu Province Centers for Disease Control and Prevention
CanSino Biologics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Years to 59 Years
Healthy volunteers
Yes
Inclusion criteria
* 6-59 years of age at the time of enrollment; * Able to provide consent or obtain consent from guardian to participate in the trial and sign an Informed Consent Form (ICF); * Able and willing to complete all the scheduled study procedures during the whole study follow-up period; * Axillary temperature ≤37.0℃; * IgG ang IgM negative for Covid-19; * Have not received any type of Covid-19 vaccines; * No contact history of Covid-19; no travel history to medium and high risk regions and abroad in the past 21 days; * Participants who are clinically determined to be healthy after checking medical history and physical examination are eligible to receive the product.
Exclusion criteria
* Medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders; * History of allergies to any ingredient of Ad5-nCoV, history of serious allergic reactions to any vaccine, history of allergies and immune diseases; * Women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the 12 months study period; * Acute febrile diseases and infectious diseases, medical history of SARS (SARS-CoV-1); * Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement for 18-59 years of age: systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg), etc; * Severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc; * Congenital or acquired angioedema/neurological edema; * Urticaria history within 1 year before receiving the study vaccine; * Asplenia or functional aspleenia; * Thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection); * Trypanophobia； * History of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months (not including corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid treatment for acute non-complicated dermatitis); * Prior administration of blood products in last 4 months; * Received other investigational drugs within 1 month before the study; * Prior administration of live attenuated vaccines within 1 month before the study; * Prior administration of subunit or inactivated vaccines within 14 days before the study; * Current anti-tuberculosis therapy; * Medical history of Covid-19 disease/infection; * Any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GMT of anti SARS-CoV-2 specific neutralizing antibody | 28 days after vaccination | GMT of anti SARS-CoV-2 specific neutralizing antibody in all groups (wild type variants test). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GMI of SARS-CoV-2 neutralizing antibody | 28 days after vaccination | GMI of anti SARS-CoV-2 specific neutralizing antibody (wild type variants test). |
| GMT of SARS-CoV-2 S protein RBD antibody | 28 days after vaccination | GMT of SARS-CoV-2 S protein RBD antibody measured by ELISA in all groups |
| Seroconversion rate of SARS-CoV-2 S protein RBD antibody | 28 days after vaccination | Seroconversion rate of SARS-CoV-2 S protein RBD antibody measured by ELISA in all groups. |
| GMI of SARS-CoV-2 S protein RBD antibody | 28 days after vaccination | GMI of SARS-CoV-2 S protein RBD antibody measured by ELISA in all groups. |
| GMT of Ad5 vector neutralizing antibody | 28 days after vaccination | GMT of anti Ad5 vector neutralizing antibody responses post vaccination in all groups |
| Seroconversion rate of SARS-CoV-2 neutralizing antibody | 28 days after vaccination | Seroconversion rate of anti SARS-CoV-2 specific neutralizing antibody (wild type variants test). |
| Stratified analysis on Ad5 vector neutralizing antibody | 28 days after vaccination | Stratified analysis based on the GMT of Ad5 vector neutralizing antibody responses post vaccination. |
| Incidence of Adverse Reactions/Events (AE/AR) | Within 30 minutes after vaccination | The occurance of Adverse Reactions/Events within 30 minutes post vaccination |
| Incidence of Serious Adverse Events (SAE) | Within 12 months after vaccination | Occurance of Serious Adverse Events (SAE) post vaccination. |
| Incidence of Adverse Events of Special Interest (AESI) | Within 12 months after vaccination | Occurance of Adverse Events of Special Interest (AESI) post vaccination. |
| GMI of Ad5 vector neutralizing antibody | 28 days after vaccination | GMI of Ad5 vector neutralizing antibody responses post vaccination in all groups |
Countries
China
Outcome results
None listed